Physician Search
![]() |
![]() |
Consuelo Wilkins, MD, MSCI, Senior Vice President for Health Equity and Inclusive Excellence for Vanderbilt University Medical Center (VUMC) and Senior Associate Dean for Health Equity and Inclusive Excellence for Vanderbilt University School of Medicine, always knew she wanted to be a physician. "Health equity was built into everything I did, even if I didn’t know it or recognize it at the time," Wilkins said. "I have always learned and believed that people are the same — everyone deserves to be healthy, and everyone should have the best opportunities to take care of themselves and their families." Click below to learn more about health equity initiatives. https://momentum.vicc.org/2021/09/everyone-deserves-to-be-healthy/ |
Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. Natasha Halasa, MD, MPH and colleagues recently published in the New England Journal of Medicine, that two doses of high-dose trivalent flu vaccine resulted in higher amounts of influenza-specific antibodies than two doses of standard dose quadrivalent vaccine. https://news.vumc.org/2023/03/02/high-dose-flu-vaccine-beneficial-for-pediatric-stem-cell-transplant-patients/ |
Inotuzumab Ozogamicin with Standard Chemotherapy Regimen for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Multiple Cancer Types
This phase I trial studies the side effects and best dose of inotuzumab ozogamicin when given with 3 and 4 drug standard chemotherapy regimen in treating patients with B-cell acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them. Chemotherapy drugs, such as daunorubicin, vincristine, cytarabine, methotrexate, and pegaspargase, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone lower the bodys immune response and are used with other drugs in the treatment of some types of cancer. Giving inotuzumab ozogamicin with standard chemotherapy may work better in treating patients with B-cell acute lymphoblastic leukemia compared to inotuzumab ozogamicin alone.
Leukemia,
Phase I
I
Oluwole, Olalekan
NCT03962465
VICCHEMP20108
A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
Multiple Cancer Types
This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation)
followed by Part B (dose expansion).
followed by Part B (dose expansion).
Lung,
Non Small Cell,
Phase I
I
Iams, Wade
NCT03819387
VICCTHOP2149
A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis
Multiple Cancer Types
This is a global, Phase 1/2, multicenter, open-label study to evaluate the safety and
efficacy of selinexor plus ruxolitinib in treatment nave myelofibrosis (MF) participants.
The study will be conducted in two phases: Phase 1a/1b and Phase 2. The Phase 1a of the study
will be dose escalation (non-randomized dose finding study) to determine the maximum
tolerated dose [MTD], recommended Phase 2 dose (RP2D), and evaluate safety and preliminary
efficacy and will follow a standard 3+3 design. The Phase 1b of the study will be dose
expansion (non-randomized efficacy exploration) at the determined RP2D to further assess the
safety and preliminary efficacy at this dose level. The Phase 2 (randomized efficacy
exploration) of the study will include MF participants who are treatment nave randomized 1:1
to receive the combination therapy of selinexor and ruxolitinib versus (vs) ruxolitinib
monotherapy.
efficacy of selinexor plus ruxolitinib in treatment nave myelofibrosis (MF) participants.
The study will be conducted in two phases: Phase 1a/1b and Phase 2. The Phase 1a of the study
will be dose escalation (non-randomized dose finding study) to determine the maximum
tolerated dose [MTD], recommended Phase 2 dose (RP2D), and evaluate safety and preliminary
efficacy and will follow a standard 3+3 design. The Phase 1b of the study will be dose
expansion (non-randomized efficacy exploration) at the determined RP2D to further assess the
safety and preliminary efficacy at this dose level. The Phase 2 (randomized efficacy
exploration) of the study will include MF participants who are treatment nave randomized 1:1
to receive the combination therapy of selinexor and ruxolitinib versus (vs) ruxolitinib
monotherapy.
Hematologic,
Phase I
I/II
Mohan, Sanjay
NCT04562389
VICCHEMP2130
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
Head/Neck
Head/Neck
To compare the effectiveness of an APCD to Usual Care in the management of lymphedema and
fibrosis (LEF) in head and neck cancer (HNC) survivors.
fibrosis (LEF) in head and neck cancer (HNC) survivors.
Head/Neck
N/A
Murphy, Barbara
NCT04797390
VICCHN2111
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Multiple Cancer Types
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to
determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy
(HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab
(EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.
The study is enrolling in the dose expansion arms.
determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy
(HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab
(EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.
The study is enrolling in the dose expansion arms.
Miscellaneous,
Phase I
I
Keedy, Vicki
NCT04485013
VICCMD2172
Nivolumab with or without Azacitidine in Treating Patients with Recurrent Resectable Osteosarcoma
Multiple Cancer Types
This phase I/II trial studies the best dose and side effects of azacitidine and how well it works with or without nivolumab in treating patients with osteosarcoma that has come back (recurrent) and can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and azacitidine together may work better compared to nivolumab alone in treating patients with osteosarcoma.
Phase I,
Sarcoma
I/II
Borinstein, Scott
NCT03628209
VICCPED2012
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Bladder
Bladder
To evaluate the activity of intravesical (IVE) administration of CG0070 in patients with
tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have
Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or
without Ta/T1 disease
tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have
Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or
without Ta/T1 disease
Bladder
III
Luckenbaugh, Amy
NCT04452591
VICCURO2152
A Study of Engineered Donor Grafts (Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Multiple Cancer Types
This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft
("Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and
Regulatory T Cells) in participants undergoing myeloablative allogeneic hematopoietic cell
transplant transplantation for hematologic malignancies.
("Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and
Regulatory T Cells) in participants undergoing myeloablative allogeneic hematopoietic cell
transplant transplantation for hematologic malignancies.
Leukemia,
Myelodysplastic Syndrome,
Phase I
I
Dholaria, Bhagirathbhai
NCT04013685
VICCCTTP2086
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Multiple Cancer Types
This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating
the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in
second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with
HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in
second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with
HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Head/Neck,
Phase I
I
Gibson, Mike
NCT03978689
VICCPHI1981
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)
Miscellaneous
Miscellaneous
Study CSL964_5001 will investigate the efficacy of AAT with corticosteroids compared with
corticosteroids alone as first line therapy for patients with high-risk acute GVHD
corticosteroids alone as first line therapy for patients with high-risk acute GVHD
Miscellaneous
III
Kitko, Carrie
NCT04167514
VICCCTT2221